Serum Pharmacokinetic Disposition and Urinary Excretion of Albendazole
Status:
Completed
Trial end date:
2017-01-20
Target enrollment:
Participant gender:
Summary
Mass drug administration (MDA) of albendazole (ABZ) to school-age and pre-school-age children
is the currently recommended strategy for controlling soil-transmitted helminthiasis (STH) in
endemic areas. Recent mathematical modelling suggests that community-wide MDA will be
required in order to interrupt transmission of STH. DEWORM3 aims to determine the feasibility
of eliminating STH through expanded and intensified MDA strategies. In order to ensure
rigorous trial results, it is crucial that the definition of such MDA coverage is informed by
unbiased, empirical data. The Centro de Investigación Veterinaria de Tandil (CIVETAN) and
Instituto de Investigaciones en Enfermedades Tropicales Universidad Nacional de Salta
collaborate on scientific research related to pharmacokinetic studies of ABZ.
This proposal describes the request for funding from DEWORM3 to conduct a study of the serum
pharmacokinetic characteristics and urinary excretion of ABZ and its metabolites in
non-infected human volunteers to better understand the use of urinary analysis of ABZ as a
measure of MDA adherence in the context of DEWORM3.
Phase:
Phase 1
Details
Lead Sponsor:
Universidad Nacional de Salta
Collaborator:
CIVETAN CONICET, Facultad de Ciencias Veterinarias, UNCPBA. Tandil